Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions. Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States. It is sold by Novartis under license from Genmab.
Read the full article on WikipediaMultiple sclerosis Clinical criteria: Treatment Phase: Continuing treatment The condition must be diagnosed as clinically definite relapsing-remitting multiple sclerosis, AND The treatment must be the sole PBS-subsidised disease modifying therapy for this condition, AND Patient must have previously received PBS-subsidised treatment with this drug for this condition, AND Patient must not show continuing progression of disability while on treatment with this drug, AND Patient must have demonstrated compliance with, and an ability to tolerate this therapy. Treatment criteria: Must be treated by a medical practitioner; OR Must be treated by a nurse practitioner in consultation with a specialist physician.
“Ofatumumab is a fully human anti-CD20 monoclonal antibody whose epitope is distinct from that of rituximab. Ofatumumab binds to a distinct epitope on small and large extracellular loops of CD20. The CD20 antigen is expressed on solely B cell lymphocytes. Compared with rituximab, ofatumumab binds more tightly to CD20 with a slower off-rate. It causes cytotoxicity in the cells that express CD20 by means of complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).”
“14 days”
Working under the parallel aged-care framework? Aged-care equivalent →